CMEOF (Creo Medical Group) YoY EBITDA Growth: -143.18% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CMEOF Creo Medical Group PLC CMEOF
29 GF Score
Price $0.23
GF Value $0.40
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Creo Medical Group YoY EBITDA Growth?

Creo Medical Group CMEOF 29 YoY EBITDA Growth is -143.18% as of Dec. 2025. GuruFocus rates CMEOF with a GF Score™ of 29/100 and a GF Value™ of $0.40 (Possible Value Trap). The stock has 6 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Creo Medical Group's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was -143.18%.

Creo Medical Group's EBITDA per Share for the six months ended in Dec. 2025 was $-0.11.

Creo Medical Group YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Creo Medical Group's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creo Medical Group YoY EBITDA Growth Chart

Creo Medical Group Annual Data
Trend Feb15 Feb16 Jun17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.23 16.82 48.31 3.26 40.45

Creo Medical Group Semi-Annual Data
Feb15 Feb16 Dec16 Jun17 Dec17 Jun18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.62 16.67 -10.00 222.22 -143.18
CMEOF
29GF Score
Creo Medical Group PLC CMEOF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Creo Medical Group YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Creo Medical Group's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.053--0.089)/ | -0.089 |
=40.45 %

Creo Medical Group's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(-0.107--0.044)/ | -0.044 |
=-143.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -143.18% mean?
Creo Medical Group (CMEOF) has a YoY EBITDA Growth of -143.18% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Creo Medical Group and its competitors.
Is Creo Medical Group's YoY EBITDA Growth too high?
Creo Medical Group's current YoY EBITDA Growth is -143.18%. Overall, Creo Medical Group has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's YoY EBITDA Growth compare to ABT and SYK?
Creo Medical Group's YoY EBITDA Growth of -143.18% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Creo Medical Group and its competitors. Creo Medical Group's current YoY EBITDA Growth is -143.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Creo Medical Group (CMEOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.40, compared to a current price of $0.23 — trading 43.6% below its estimated fair value. The current YoY EBITDA Growth is -143.18%. Creo Medical Group's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current YoY EBITDA Growth is -143.18% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creo Medical Group (CMEOF) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of $0.23 is trading 43.6% below its estimated GF Value™ of $0.40. GuruFocus considers Creo Medical Group to be Possible Value Trap.

Key valuation signals for CMEOF:

  • YoY EBITDA Growth: -143.18%
  • GF Value™: $0.40 vs. price of $0.23 (43.6% below fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Creo Medical Group Business Description

Other Exchanges CREO:UK
Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
29GF Score

Get the complete analysis for CMEOF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.23
Price
$0.40
GF Value